Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.
Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 131
- Registration Number
- NCT04889118
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital (0609), Nanjing, Jiangsu, China
🇨🇳Beijing Cancer Hospital (0601), Beijing, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Center (0602), Guangzhou, Guangdong, China
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 35
- Registration Number
- NCT04865887
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸Medstar Washington Hospital Center, Washington, District of Columbia, United States
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT04865289
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center ( Site 2500), Shanghai, Shanghai, China
🇨🇳Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou, Zhejiang, China
🇨🇳Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei, Anhui, China
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT04848337
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Winship Cancer Instituted of Emory University, Atlanta, Georgia, United States
🇺🇸Oregon health, Portland, Oregon, United States
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT04784247
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Floor Backes, MD
- Target Recruit Count
- 38
- Registration Number
- NCT04781088
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 480
- Registration Number
- NCT04776148
- Locations
- 🇨🇦
NSHA-QEII Health Sciences Centre-Dickson Bldg-Dept. of Medical Oncology ( Site 0200), Halifax, Nova Scotia, Canada
🇯🇵Shizuoka Cancer Center ( Site 1706), Nagaizumi, Shizuoka, Japan
🇩🇰Herlev and Gentofte Hospital-Department of Oncology ( Site 0704), Copenhagen, Hovedstaden, Denmark
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 554
- Registration Number
- NCT04770896
- Locations
- 🇦🇹
Medizinische Universität Innsbruck; Universitätsklinik für Innere Medizin I, Innsbruck, Austria
🇦🇹Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria
🇦🇹Universitätsklinikum St. Pölten; Innere Medizin 2, St. Pölten, Austria
Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT04769908
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 335
- Registration Number
- NCT04763408
- Locations
- 🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇩🇪Eisai Trial Site #2, Berlin, Germany
🇩🇪Eisai Trial Site #6, Munich, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.